Axogen reports Q4 2023 revenue $42.9M (+18.7% YoY); 2024 revenue guidance $177-181M

Axogen, Inc.

Q4 net loss $3.9M ($0.09/share) vs $5.4M loss in Q4 2022; adjusted EBITDA turned positive at $0.6M.
Full-year 2023 revenue $159.0M (+14.7% YoY); net loss $21.7M vs $28.9M in 2022.
Gross margin declined: Q4 78.7% vs 83.0%; FY 80.4% vs 82.6%. Guidance expects 76-79% for 2024.
FDA pre-BLA agreement for Avance nerve graft; rolling submission in Q3 2024, potential approval mid-2025.
Avive+ Soft Tissue Matrix launch planned in Q2 2024; core accounts grew 13.3% to 376.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.5

Axogen, Inc. updated its the fourth quarter and full-year ended December 31, 2023 guidance (raised).

Period: the fourth quarter and full-year ended December 31, 2023
Guidance: raised
Result: reported results

Exact text from the filing

On March 5, 2024 Axogen, Inc. (the “Company”) issued a press release announcing its fourth quarter and full year 2023 financial results.

View on SEC.gov

Browse all earnings releases →

Axogen, Inc. filing history →

Source: SEC EDGAR

accession 0000805928-24-000025

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.